August commemorates Psoriasis Awareness month and is used as an opportunity to educate and inform on a range of topics varying from treatment, causes, triggers and management of the inflammatory and often irritating disease.
Psoriasis, which manifests most often as plaque psoriasis, is a chronic, relapsing, inflammatory skin disorder, with a strong genetic basis. Plaque psoriasis is rarely life threatening, but it often is intractable to treatment.
Did you know?
• The worldwide estimated prevalence of Plaque Psoriasis is ~51 million cases
• The extent and duration of plaque psoriasis is highly variable from patient to patient.
• Up to 10-20% of patients with plaque psoriasis also experience psoriatic arthritis
Adalvo has ventured within the auto-immune segment and is offering Apremilast Film-Coated Tablets, which is indicated in the treatment of Psoriatic Arthritis and Psoriasis. Our product has been developed based on the reference brand Otezla Film-Coated Tablets, which currently represents one of the few comfortable and compliant oral treatments for this disease. The brand sold approximately $3.5bn globally in 2021, having a significant growth potential with Global 3Y CAGR at 15%, according to IQVIA.
Adalvo’s DCP submission is schedule for January 2023 and based on these timelines, we believe we will be among the first companies to file in Europe.
Adalvo is working on several interesting auto-immune projects, as depicted below. This highlights our ability to offer differentiated, value-added products to our partners.
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.